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IZINDABA
‘They said according to our last
discussions I was out of theatre and that
was it,’ she said.
On 23 June this year, nearly a month
after her written request to once again
do theatre work, Dr B Mbule, the acting
CEO, wrote to her asking her to
elaborate.
‘You state that you are more than
willing to work in all the theatre
disciplines. Does this statement include
scrubbing for all emergencies, coming
into theatre for example, any evacuation
for retained products of conception? We
await your answer in writing.’
The Doctors For Life’s voluntary legal
advisor, John Smyth, QC, responded by
asking what conditions, if any, the
hospital wished to impose if she were to
return to theatre.
No reply was forthcoming and all
subsequent queries were referred to the
Gauteng Health Ministry.
Smyth said that by early September
the Ministry had yet to reply to 3
subsequent letters.
Charles told the SAMJ that she took
sick leave to undergo psychotherapy
‘because I was starting to believe that I
was the only one, the real
troublemaker’.
She subsequently ‘decided there is no
way out of this and it’s not fair, so I
resigned’.
She began a new surgery job with the
Vereeniging Medi-Clinic in September –
after being assured that they have no
TOP ward.
Doctors For Life are demanding
Charles be allowed to return to theatre
work, R50 000 in damages and an
unconditional apology.
Smyth told the SAMJ that he expected
a preliminary Equality Court hearing by
October.
He filed papers in late August under
the Promotion of Equality and
Prevention of Unfair Discrimination
Act. 
‘We may be referred to the High
Court if the Equity Court deems it a
constitutional issue, and it could then
leap-frog to the Constitutional Court,’
he added.
The State Attorney dealing with the
matter, Mr M Lakabe, confirmed having
taken instructions from senior managers
at Kopanong Hospital but said he had
yet to receive anything on paper from
lawyers for Charles.
‘At this stage it remains just a threat,’
he said.
Chris Bateman
Just days after the Cape High Court
dismissed with costs the New Clicks
and Pharmaceutical Society of  South
Africa’s (PSSA’s) attempt to suspend the
new national law on dispensing fees,
pharmacists in Cape Town closed their
doors in protest and fear of prosecution.
Across the Cape Peninsula pharmacists
put up notices objecting to ‘untenable’
dispensing fee ceilings and advising
customers to go to public hospitals for
their drugs.
The closures were sparked, some said,
by a complaint lodged with the Fish
Hoek police that one of their number
had flouted the new dispensing rules by
charging more than the maximum
professional fee of R26 (or 26% of any
drug below R100) for scheduled
medicines.
For Schedule 1 and 2 medicines,
licensed dispensers may charge a
maximum professional fee of 16% of the
single exit price, up to a maximum fee
of R16.
In what has been a united,
determined, and some say clumsy effort
by government agencies to make
medicines more widely affordable, the
national health department’s head of
legal services, Debbie Paermain, told
customers they could help keep
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Pinelands pharmacists Denis Landau and Dinesh Dalla comb the dissenting minority
judgment of Judge Jeanette Traverso for any potentially profit-saving pearls after being hit by
the seemingly landmark judgment last month. Picture: Chris Bateman
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chemists in line by reporting
overcharging.
The anger and fear at what
pharmacists and dispensing doctors say
spells economic doom, led to a virtual
Peninsula-wide shut down of chemists
for a day.
The long-awaited court verdict
included a little-known but powerfully
dissenting judgment by Judge Jeanette
Traverso.
It was almost point for point at odds
with her two colleagues, Judges James
Yekiso and John M Hlophe (Judge
President of the Cape High Court).
She made it clear that she would have
allowed the review to succeed with
costs, labelling the manner in which the
Pricing Committee conducted itself
during oral presentations as ‘improper’
and ‘haphazard’.
Judge Traverso said leaving it mainly
to Department of Health officials to
receive and summarise oral submissions
by stakeholders had deprived the
stakeholders of the collective wisdom
and expert opinions of the Pricing
Committee.
The role played by the health
department in the receipt of oral
submissions was ‘analagous to the
interference of non-members of a
committee in the deliberations and
decision-making process’.
She said she also found it ‘impossible’
to determine how the single exit price
was to be calculated, because the
definitions of and regulations around
the logistics fee it included were
contradictory.
As for manufacturers using
‘international benchmarks’ when
pricing and/or applying to the health
minister for annual price increases,  ‘no
objectively ascertainable basket of
countries’ was stipulated.
Judge Traverso said the Pricing
Committee misconstrued their function
and the purpose of  the enabling
legislation, and therefore took into
account ‘irrelevant considerations’,
forgetting that the emphasis was on
‘transparency and consistency’.
The Pricing Committee saw their role
as one of reducing the prices of
medicines by statutory price controls ‘at
all costs’.
Although Clicks and the PSSA had
made it clear in their founding papers
that a pharmacy’s mark-up would have
to be well in excess of 26%/R26 in order
to remain viable, Traverso ‘searched in
vain for any reasoned consideration’ of
whether this would cover the
pharmacists’ operating costs.
‘In my view it is clear that the Pricing
Committee mistakenly assumed that
this would be equivalent to a profit in
the region of 25 - 26%’.
The true economic impact of fixing
the dispensing fee at this level was
‘never discussed in any rational
manner’.
Judge Traverso said she was left with
the very distinct impression that the fee
fixed was ‘no more than a thumb suck
based on a very simplistic “one size fits
all” approach’.
To suggest that pharmacists were at
large to charge fees stipulated in the
tariff of fees (that had no force of law)
was seemingly ‘irrational and contrary
to the entire scheme of the Act’.
She dismissed national pharmacy
planning chief Dr Humphrey Zokufa’s
contention that no ‘substantial evidence’
was presented to show that any
pharmacy would be devastated by the
recommended dispensing fee.
This was inconsistent with the Pricing
Committee chairperson, Professor Di
McIntyre’s evidence that New Clicks
and ‘a host’ of interested parties
testified that the new dispensing fee
would condemn pharmacies to operate
at a loss.
The Committee appear to have
adopted an indifferent attitude to the
allegation that their recommendations
would lead to the closure of many
pharmacies and that this would in turn
deprive consumers of the medicines and
primary health care services which
pharmacies provide.
Instead the Committee had
suggested, with no sound economic
basis, that pharmacists expand their
‘front-shop’ activities (cosmetics, gifts,
etc.) to avoid potential financial disaster.
Traverso said that on the respondents’
own papers, the current regulatory
scheme left it to pharmacists to charge
whatever they wanted for certain
professional services.
She said the Pricing Committee’s
recommendations on the dispensing fee
were premised on a ‘confused
conflation between mark-up and profit’.
The regulations would ‘materially
and adversely’ affect the rights of the
public or, at the very least, a group or
class of the public, Traverso concluded.
Judge Yekiso and Judge Hlophe
however said that most pharmacies’
front-shop activities accounted for a
relatively small proportion of sales (less
than 17% on average), yet the front-
shop occupied about 80% of floor space.
The conclusion was therefore
‘inescapable’ that costs such as rent,
utilities and non-pharmacist staff were
attributable to front-shop activities.
It was mainly for this reason that the
Pricing Committee concluded that it
was undesirable for a patient or
consumer to bear costs that were not
connected to dispensing services.
The two judges described as ‘sheer
speculation’ assertions that the
regulations would cause wide-scale
harm to the pharmacy profession and
result in significantly fewer pharmacies.
The Pricing Committee had been at
pains to acquire information
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demonstrating the actual costs of
dispensing medicine and the number of
prescriptions attended to in any one day
of a business operation (the PSSA said
this came to a daily average of 70).
While it was given front-shop costs,
the Pricing Committee was not given
the necessary breakdown reflecting the
complete costs of dispensing activities.
The Committee had struck a balance
between the pharmacists’ need for
professional remuneration and the need
to make medicines and scheduled
substances affordable.
‘Just because the applicants might
disagree on the dispensing fee that was
finally recommended and accepted,
does not in itself mean that it  is
inappropriate,’ Judge Yekiso wrote.
The majority judgment said
regulations that contemplated
publication by the Director-General of
Health of a methodology for
conforming to international pricing
benchmarks did in fact exist.
This kind of information ‘ought to be
readily accessible’ to manufacturers and
importers of drugs, either through
international price lists or trade
representatives.
There was no evidence to suggest that
manufacturers and importers had had
any difficulty in complying with the
single exit price regulation since it was
applied on 2 June  this year.
The judges said they were therefore
unable to find any basis for the
‘considerable confusion’ complained of
between the determination of the drugs
price and the logistics fee.
An application for leave to appeal
against the majority ruling due on 2
September  was postponed until 20
September.
In the meantime pharmacists began
charging for deliveries, phone calls to
medical aids, faxes and consultations,
with several adding on an
‘administration fee’ of between 10% and
15%, something the Department seemed
legally confused about.
Zokufa  urged customers to be aware
that they could be ‘charged for
additional things’, and was initially
unsure whether the ad hoc
‘administration fee’ was legal.
While some medicines have come
down in price, certain private hospitals
have increased their ward and theatre
tariffs to compensate for the expected
loss in profits.
Zokufa said the regulations were
‘firmly in place’ until the outcome of the
appeal application, or unless an interim
order to have them suspended was
granted.
Chris Bateman
100 years ago: Pretoria Medical Society
A meeting was held on 13 May in the Government Library. Dr Kay read a paper on malaria. He commenced by shewing that
there are local differences in malaria, every malarious district having some peculiar symptom or symptoms. After enumerating
the common symptoms, he went on to describe the parasite and its mode of introduction. In South Africa, as he pointed out, it
is common for ague to be at first quotidian, then tertian, and quartan as convalescence approaches, cases varying greatly
according to the amount of poison introduced into the system. Latent malaria is exceedingly common in malarious districts,
where nearly all affections are complicated with it, or bear its impress. Dr Kay traced the advent of malaria into Pretoria,
where, he contended, the opening of the soil on various occasions had much to do with outbreaks, the mosquito being
unknown in those days, and he suggested the possibility of infection through the lungs as well as by the mosquito. As regards
treatment, he laid stress upon Warburg’s tincture preceded by a weak purge, also on the hypodermic use of quinine, and in
children its introduction per rectum, and he deprecated the use of tabloids. 
50 years ago: Colds and controls
The common cold is one of many diseases for which wild claims for certain remedies have been made. Thus extravagant claims
were made a few years ago for certain anti-histamine drugs, but when hundreds of patients were treated by an expert
committee, half of the patients receiving tablets containing the drug while the other half received inert dummy tablets, it was
found on statistical analysis, that the results were almost as good with the dummy as with the drug. It is interesting to note too
that unpleasant side-effects attributed to the drug occurred with the same frequency in both groups... The two groups should
be as nearly equal as possible for the experiment [and] one absolutely essential requirement for a valid experiment is that
allocation to the two groups must be random. Errors of assessment must be avoided, best by the use of the double blind
technique, in which neither the doctor nor the patient knows which patients receive dummy treatment; the controls receive
dummy tablets similar in appearance, taste and smell to the real tablets... It is only by proper planning of an experiment and
precautions such as indicated by Gaddum1 that ‘the subjective opinions of a group of patients can be interpreted with
mathematical precision’. 
1. Gaddum JH. Proc Roy Soc Med 1954; 47: 195.  
